Yahoo Web Search

  • FirefoxTry Yahoo Search on Firefox »
    1. Highlighted among the posters will be new preclinical data on Morphotek's proprietary antibody-drug conjugate (ADC) technology, REsidue-SPEcific Conjugation TechnologyTM (RESPECTTM), ...

    2. Immunomedics is a clinical-stage biotech developing what are called antibody drug conjugates (ADCs) for the treatment of various forms of cancer. ADCs are in essence chemotherapy attached ...

    3. The presentation “Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient” occurred at the 43rd Annual Meeting ...

    4. But while the price before discounts and rebates to insurers is far more expensive than topical medicines and steroids currently used to treat eczema, it is less pricey than other injectable ...

    5. Avelumab, a human anti-PD-L1 antibody, will be marketed by the trade name of Bavencio for intravenous use for the treatment of adults and pediatric patients 12 years and older with metastatic ...

    6. The submission was supported by data from the phase III REGAIN study. Recently, the FDA accepted the supplemental Biologics License Application (sBLA) filed for Soliris for the...

    7. (Janssen) has filed an IND for an antibody discovered using Ligand’s OmniAb technology. This IND filing results in a $1 million milestone payment to Ligand. “This milestone represents ...

    8. Story Stocks from Briefing.com

      Briefing.com via Yahoo Finance1 hour ago

      Tesaro also announced a substantial expansion of its niraparib clinical development program in combination with an anti-PD-1 antibody (e.g. Merck's Keytruda or Bristol-Myers' Opdivo).

    9. (CGEN), a therapeutic discovery company, announced today the selection of COM902 as the lead clinical antibody candidate for its CGEN-15137/TIGIT T cell checkpoint inhibitor program in ...

    1. 12345203 results